WILDA WAHYUNI, - (2025) ANALISIS BIAYA PENGGUNAAN OBAT SERTRALINE DAN FLUOXETINE PADA PASIEN DIAGNOSIS ANSIETAS DEPRESI RAWAT JALAN DI RUMAH SAKIT JIWA PROVINSI JAWA BARAT. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A233030_Title.pdf Download (851kB) |
|
Text
S_PSSF_A233030_Chapter1.pdf Restricted to Repository staff only Download (27kB) |
|
Text
S_PSSF_A233030_Chapter2.pdf Restricted to Repository staff only Download (590kB) |
|
Text
S_PSSF_A233030_Chapter3.pdf Restricted to Repository staff only Download (502kB) |
|
Text
S_PSSF_A233030_Chapter4.pdf Restricted to Repository staff only Download (497kB) |
|
Text
S_PSSF_A233030_Chapter5.pdf Restricted to Repository staff only Download (8kB) |
|
Text
S_PSSF_A233030_Appendix.pdf Restricted to Repository staff only Download (2MB) |
Abstract
Depresi merupakan gangguan mental dengan prevalensi tinggi yang berdampak pada kualitas hidup dan menimbulkan beban ekonomi. Terapi farmakologi dengan selective serotonin reuptake inhibitors (SSRI) seperti sertraline dan fluoxetine banyak digunakan, namun keduanya memiliki efektivitas dan biaya berbeda. Penelitian ini bertujuan menganalisis efektivitas biaya penggunaan sertraline dan fluoxetine pada pasien depresi rawat jalan di Rumah Sakit Jiwa Provinsi Jawa Barat periode Januari – Desember 2024. Penelitian menggunakan desain non- eksperimental dengan pendekatan cross-sectional berbasis data sekunder dari rekam medis dan data keuangan pasien. Pengambilan sampel dilakukan secara purposive non-random sampling dengan pendekatan total sampling, berdasarkan kriteria inklusi dan eksklusi yang telah ditetapkan. Hasil penelitian menunjukkan bahwa penggunaan sertraline merupakan pilihan yang paling costeffectiveness dengan nilai ACER sebesar Rp. 400.586 dibandingkan fluoxetine yang memiliki nilai ACER Rp. 1.294.288. Selain itu, sertraline lebih aman dengan persentase pasien yang tidak membutuhkan terapi efek samping sebesar 40,0%, dibanding fluoxetine dengan persentase sebesar 26,7%. ------ Depression is a mental disorder with a high prevalence that affects quality of life and creates an economic burden. Pharmacological therapy using selective serotonin reuptake inhibitors (SSRIs) such as sertraline and fluoxetine is widely used, but both differ in terms of effectiveness and cost. This study aims to analyze the cost-effectiveness of sertraline and fluoxetine in outpatients with depression at the West Java Provincial Mental Hospital during the period of January – December 2024. The study employed a non-experimental design with a cross- sectional approach based on secondary data from medical records and patients’ financial data. Sampling was carried out using purposive non-random sampling with a total sampling approach, based on predetermined inclusion and exclusion criteria. The results showed that sertraline wasthe most cost-effective option with an ACER value of Rp 400,586 compared to fluoxetine, which had an ACER value of Rp 1,294,288. In addition, sertraline was found to be safer, with 40.0% of patients not requiring side effect therapy, compared to 26.7% of patientsreceiving fluoxetine.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | Depresi, sertraline, fluoxetine, cost-effectiveness analysis, farmakoekonomi. ------ Depression, sertraline, fluoxetine, cost-effectiveness analysis, pharmacoeconomics |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 19 Nov 2025 03:55 |
| Last Modified: | 19 Nov 2025 03:55 |
| URI: | http://repository.stfi.ac.id/id/eprint/3495 |
Actions (login required)
 |
View Item |
